It is time once again for my once-yearly set of unsolicited thoughts on biotech startups that I’d like to see join those already working hard on the basis for human rejuvenation. The industry is growing rapidly, but patchily. Partial reprogramming has received enormous attention, as has the development of senolytics. Meanwhile, other important goals in rejuvenation research languish, or presently have only one or two companies involved in clinical translation of promising academic projects. Many plausible pa…
Request for Startups in the Rejuvenation Biotechnology Space, 2023 Edition
It is time once again for my once-yearly set of unsolicited thoughts on biotech startups that I’d like to see join those already working hard on the basis for human rejuvenation. The industry is growing rapidly, but patchily. Partial reprogramming has received enormous attention, as has the development of senolytics. Meanwhile, other important goals in rejuvenation research languish, or presently have only one or two companies involved in clinical translation of promising academic projects. Many plausible pa…